Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822310 | 1.00 | MAPK1 (0.45) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2823947 | 0.91 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2823943 | 0.91 | MAPK1 (0.42) | MAPK1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL2827292 | 0.89 | TRPM8 (0.38) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2827290 | 0.89 | TRPM8 (0.38) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2825383 | 0.87 | MAPK1 (0.45) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2825379 | 0.87 | MAPK1 (0.45) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2826904 | 0.83 | MAPK1 (0.46) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2826906 | 0.83 | MAPK1 (0.46) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A | |
| SCHEMBL2823984 | 0.83 | MAPK1 (0.46) | MAPK1KDM4EALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | MAPK1 2141/4885KDM4E 3190/4885ALDH1A1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.